This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Statistics and Research Methods  • Women's Health  • Pregnancy and Breast Feeding  • Prognosis/ Outcomes  • Pediatrics  • Depression  • Psychopharmacology  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Thomas R. Einarson, PhD; Gideon Koren, MD; Adrienne Einarson, RN

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article by Oberlander et al¹ attempts to address potential perinatal adverse effects of selective serotonin reuptake inhibitor (SSRI) use during pregnancy while accounting for depression in the mother. However, we believe that some of the conclusions they made are not supported by the data presented.

In the conclusion in the abstract, 2 statements they made were not supported by the data. They conclude that (1) " . . . exposure was associated with an increased risk of low birth weight. . . . " The definition of low birth weight is lower than 2500 g² and in neither the introduction (ie, statement of purpose) nor the "Methods" section, did the authors indicate that low birth weight was an outcome that they investigated. They mention only average weight of newborns and the proportion falling lower than the 10th percentile (ie, small for gestational age). In fact, the rates . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Neonatal Outcomes After Prenatal Exposure to Selective Serotonin Reuptake Inhibitor Antidepressants and Maternal Depression Using Population-Based Linked Health Data
Tim F. Oberlander, William Warburton, Shaila Misri, Jaafar Aghajanian, and Clyde Hertzman
Arch Gen Psychiatry. 2006;63(8):898-906.
ABSTRACT | FULL TEXT